AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9457834 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 Gy/2 fractions (group B)
Number of subjects: 172
Study 9457834 — intervention group
Group type: EXPERIMENTAL
Intervention: 18 Gy/3 fractions (group C)
Number of subjects: 172
Study 9457834 — intervention group
Group type: COMPARATOR
Intervention: Fractionated brachytherapy
Number of subjects: 172
Study 7641062 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose (F)
Number of subjects: 7
Study 7641062 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose + Arginine + Citric Acid (GAC)
Number of subjects: 7
Study 7641062 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 2666484 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal scopolamine (TS) patch
Number of subjects: 10
Study 2666484 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 10
Study 1093308 — intervention group
Group type: EXPERIMENTAL
Intervention: Flavoxate
Number of subjects: 382
Study 1093308 — intervention group
Group type: COMPARATOR
Intervention: Phenazopyridine
Number of subjects: 382
Study 28567530 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate definitive individualized abutments (T)
Number of subjects: 16
Study 28567530 — intervention group
Group type: COMPARATOR
Intervention: Control individualized abutments (C)
Number of subjects: 16
Study 27707817 — intervention group
Group type: EXPERIMENTAL
Intervention: evolocumab 420 mg
Number of subjects: 0
Study 27707817 — intervention group
Group type: EXPERIMENTAL
Intervention: evolocumab 140 mg
Number of subjects: 0
Study 27707817 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study 24130144 — intervention group
Group type: EXPERIMENTAL
Intervention: Camel Snus (Snus to Cope)
Number of subjects: 57
Study 24130144 — intervention group
Group type: EXPERIMENTAL
Intervention: Camel Snus (Snus to Reduce)
Number of subjects: 57
Study 24130144 — intervention group
Group type: COMPARATOR
Intervention: No-supply group (Control)
Number of subjects: 57
Study 22751965 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual withdrawal with restricted symptomatic medication and prophylactics from Day 1 (Group A)
Number of subjects: 98
Study 22751965 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-month drug-free period with multidisciplinary education in groups (Group B)
Number of subjects: 98
Study 20378841 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.27% glucose-based PET
Number of subjects: 90
Study 20378841 — intervention group
Group type: COMPARATOR
Intervention: 3.86% glucose-based PET
Number of subjects: 90
Study 18691293 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific Immunotherapy (SIT)
Number of subjects: 28
Study 18691293 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 28
Study 15911192 — intervention group
Group type: EXPERIMENTAL
Intervention: Poster campaign in Geneva (exposed group)
Number of subjects: 1955
Study 15911192 — intervention group
Group type: COMPARATOR
Intervention: Control group in Neuchatel
Number of subjects: 1955
Study 15911192 — intervention group
Group type: COMPARATOR
Intervention: Comparison of before-after change between Geneva and Neuchatel
Number of subjects: 1955
Study 15911192 — intervention group
Group type: EXPERIMENTAL
Intervention: Poster campaign
Number of subjects: 1955
Study 12891212 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (23 patients with 23 lesions)
Number of subjects: 44
Study 12891212 — intervention group
Group type: COMPARATOR
Intervention: Control group (21 patients with 21 lesions)
Number of subjects: 44
Study 11273876 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid (15 mg intravenously three times weekly)
Number of subjects: 66
Study 11273876 — intervention group
Group type: COMPARATOR
Intervention: Folinic acid (16.1 mg intravenously three times weekly)
Number of subjects: 66
Study 9126714 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (participants)
Number of subjects: 73
Study 9126714 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-participants)
Number of subjects: 73
Study 8247194 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual captopril (25 mg)
Number of subjects: 0
Study 8247194 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual nifedipine (10 mg)
Number of subjects: 0
Study 8247194 — intervention group
Group type: COMPARATOR
Intervention: Sublingual prazosin (2 mg)
Number of subjects: 0
Study 3930305 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 capsules of carotenoids (10 mg beta‐carotene + 15 mg canthaxanthin per capsule)
Number of subjects: 14
Study 3930305 — intervention group
Group type: COMPARATOR
Intervention: 4 capsules of carotenoids (10 mg beta‐carotene + 15 mg canthaxanthin per capsule)
Number of subjects: 14
Study 3930305 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (4 and 6 capsules)
Number of subjects: 14
Study 31012803 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium
Number of subjects: 96
Study 31012803 — intervention group
Group type: EXPERIMENTAL
Intervention: Choline-Magnesium
Number of subjects: 96
Study 31012803 — intervention group
Group type: EXPERIMENTAL
Intervention: Choline
Number of subjects: 96
Study 31012803 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 29901456 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrocautery ablation (ECA)
Number of subjects: 49
Study 29901456 — intervention group
Group type: COMPARATOR
Intervention: Argon plasma coagulation (APC)
Number of subjects: 49
Study 27776679 — intervention group
Group type: EXPERIMENTAL
Intervention: Quitline services (QL) including a motivational interview, 6 weeks of nicotine patches and gum, a referral to the QL, a booster call, and a quitline brochure.
Number of subjects: 778
Study 27776679 — intervention group
Group type: COMPARATOR
Intervention: Control group received only the quitline brochure.
Number of subjects: 778
Study 24984081 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral Nutrition (PN)
Number of subjects: 116
Study 24984081 — intervention group
Group type: COMPARATOR
Intervention: Fluid therapy
Number of subjects: 116
Study 22551742 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment by a homeopath
Number of subjects: 24
Study 20202890 — intervention group
Group type: EXPERIMENTAL
Intervention: One-step hydrogen peroxide (H2O2) lens care system (Clear Care)
Number of subjects: 26
Study 20202890 — intervention group
Group type: COMPARATOR
Intervention: Multi-purpose disinfecting system (MPDS) (OPTI-FREE RepleniSH)
Number of subjects: 26
Study 20202890 — intervention group
Group type: EXPERIMENTAL
Intervention: Both systems (H2O2 and MPDS)
Number of subjects: 26
Study 17506881 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracheck Pf rapid diagnostic test (RDT)
Number of subjects: 180
Study 17506881 — intervention group
Group type: COMPARATOR
Intervention: Artemisinin-based combination therapy (ACT)
Number of subjects: 180
Study 15703163 — intervention group
Group type: EXPERIMENTAL
Intervention: Gly(16)/Glu(27)
Number of subjects: 64
Study 15703163 — intervention group
Group type: COMPARATOR
Intervention: Gly(16)/Gln(27)
Number of subjects: 64
Study 15703163 — intervention group
Group type: COMPARATOR
Intervention: Arg(16)/Gln(27)
Number of subjects: 64
Study 15703163 — intervention group
Group type: EXPERIMENTAL
Intervention: Brachial intra-arterial propranolol infusion in Gly(16)/Glu(27)
Number of subjects: 64
Study 15703163 — intervention group
Group type: COMPARATOR
Intervention: Brachial intra-arterial propranolol infusion in Arg(16)/Gln(27)
Number of subjects: 64
Study 11174795 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper limb exercise training (n = 26)
Number of subjects: 52
Study 11174795 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower limb exercise training (n = 26)
Number of subjects: 52
Study 11174795 — intervention group
Group type: COMPARATOR
Intervention: Control group (lifestyle advice only, n = 15)
Number of subjects: 52
Study 9633736 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose intravenous methylprednisolone (IVMP)
Number of subjects: 0
Study 9633736 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower dose intravenous methylprednisolone (IVMP)
Number of subjects: 0
Study 8164314 — intervention group
Group type: EXPERIMENTAL
Intervention: Sebacate (6.6 g/h)
Number of subjects: 12
Study 8164314 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 12
Study 8164314 — intervention group
Group type: EXPERIMENTAL
Intervention: Sebacate
Number of subjects: 12
Study 3356852 — intervention group
Group type: COMPARATOR
Intervention: Maternal avoidance of cow's milk and egg during pregnancy
Number of subjects: 210
Study 3356852 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal intake of cow's milk and egg during lactation
Number of subjects: 210
Study 3356852 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal cow's milk exposure before 6 months
Number of subjects: 210
Study 3356852 — intervention group
Group type: COMPARATOR
Intervention: High levels of maternal IgG, IgA, or IgM antibodies to food at delivery
Number of subjects: 210
Study 1944900 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetyl-L-carnitine
Number of subjects: 130
Study 1944900 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study 799559 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (200 mg daily)
Number of subjects: 45
Study 799559 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 45
Study 31119578 — intervention group
Group type: EXPERIMENTAL
Intervention: Infected patients
Number of subjects: 466
Study 31119578 — intervention group
Group type: EXPERIMENTAL
Intervention: Eosinopenia in infected patients
Number of subjects: 466
Study 31119578 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep eosinopenia in infected patients
Number of subjects: 466
Study 31119578 — intervention group
Group type: EXPERIMENTAL
Intervention: WBC count modifications with elevated CRP (> 40 mg/L) or fever (> 38.5 °C) in infected patients
Number of subjects: 466
Study 31119578 — intervention group
Group type: COMPARATOR
Intervention: Control group of uninfected patients
Number of subjects: 466
Study 28035663 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-class U-net
Number of subjects: 66
Study 28035663 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-class U-nets
Number of subjects: 66
Study 28035663 — intervention group
Group type: COMPARATOR
Intervention: Atlas-based method
Number of subjects: 66
Study 28035663 — intervention group
Group type: COMPARATOR
Intervention: Sheetness-based method
Number of subjects: 66
Study 26448540 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial incentive of £15 per depot injection over 12 months
Number of subjects: 141
Study 26448540 — intervention group
Group type: COMPARATOR
Intervention: Usual health services
Number of subjects: 141
Study 26448540 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial incentive intervention
Number of subjects: 141
Study 23568049 — intervention group
Group type: EXPERIMENTAL
Intervention: High-volume polyethylene glycol (PEG) 60 mL kg⁻¹ day⁻¹
Number of subjects: 240
Study 23568049 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-volume polyethylene glycol plus bisacodyl (BPEG) 30 mL kg⁻¹ day⁻¹ plus oral bisacodyl 10 to 15 mg/day
Number of subjects: 240
Study 23568049 — intervention group
Group type: EXPERIMENTAL
Intervention: Sennosides 2 mg kg⁻¹ day⁻¹
Number of subjects: 240
Study 21835301 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 1442
Study 21835301 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1442
Study 19349325 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranolazine
Number of subjects: 4918
Study 19349325 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranolazine in diabetic patients
Number of subjects: 4918
Study 19349325 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranolazine in patients without diabetes
Number of subjects: 4918
Study 19349325 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4918
Study 17074143 — intervention group
Group type: EXPERIMENTAL
Intervention: UPBSCT
Number of subjects: 63
Study 17074143 — intervention group
Group type: COMPARATOR
Intervention: UBMT
Number of subjects: 63
Study 16332607 — intervention group
Group type: EXPERIMENTAL
Intervention: Process-oriented breastfeeding training
Number of subjects: 0
Study 16332607 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 16332607 — intervention group
Group type: EXPERIMENTAL
Intervention: Postnatal nurses in the intervention group
Number of subjects: 0
Study 16332607 — intervention group
Group type: EXPERIMENTAL
Intervention: Midwives in the intervention group
Number of subjects: 0
Study 16332607 — intervention group
Group type: COMPARATOR
Intervention: Midwives in the control group
Number of subjects: 0
Study 11587253 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium-fortified milk supplement (3 L weekly in the first year)
Number of subjects: 115
Study 11587253 — intervention group
Group type: COMPARATOR
Intervention: Usual diet
Number of subjects: 115
Study 11587253 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium-fortified milk supplement
Number of subjects: 115
Study 9623792 — intervention group
Group type: EXPERIMENTAL
Intervention: Wallach Endocell
Number of subjects: 370
Study 9623792 — intervention group
Group type: COMPARATOR
Intervention: Vabra
Number of subjects: 370
Study 9623792 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocell
Number of subjects: 370
Study 8162479 — intervention group
Group type: EXPERIMENTAL
Intervention: Active low level laser therapy (LLLT)
Number of subjects: 40
Study 8162479 — intervention group
Group type: COMPARATOR
Intervention: Placebo laser
Number of subjects: 40
Study 3144923 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg.kg‐1 sodium valproate intravenously over 20 min
Number of subjects: 39
Study 3144923 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg.kg‐1 ketoprofen intravenously over 20 min
Number of subjects: 39
Study 3144923 — intervention group
Group type: COMPARATOR
Intervention: Placebo (5% dextrose)
Number of subjects: 39
Study 31971045 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural intervention (CBI) for 10 weeks
Number of subjects: 82
Study 31971045 — intervention group
Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 82
Study 29961279 — intervention group
Group type: EXPERIMENTAL
Intervention: Actinomycin D (Act‐D)
Number of subjects: 200
Study 29961279 — intervention group
Group type: EXPERIMENTAL
Intervention: Floxuridine+Act‐D+vincristine (FAV) or Floxuridine+Act‐D+etoposide+vincristine (FAEV)
Number of subjects: 200
Study 29961279 — intervention group
Group type: COMPARATOR
Intervention: EMA/CO or EMA/EP
Number of subjects: 200
Study 27916783 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide plus insulin
Number of subjects: 17
Study 27916783 — intervention group
Group type: COMPARATOR
Intervention: Insulin treatment (control group)
Number of subjects: 17
Study 25448243 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural steroid injections (SESIs) - 80mg of triamcinolone in normal saline
Number of subjects: 50
Study 25448243 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 50
Study 25448243 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural steroid injections (SESIs)
Number of subjects: 50
Study 23795734 — intervention group
Group type: EXPERIMENTAL
Intervention: DPCP sensitization in mountaineers (high altitude)
Number of subjects: 37
Study 23795734 — intervention group
Group type: COMPARATOR
Intervention: DPCP sensitization in controls (sea level)
Number of subjects: 37
Study 21806903 — intervention group
Group type: EXPERIMENTAL
Intervention: Viewing positive images of dentistry (n=35)
Number of subjects: 70
Study 21806903 — intervention group
Group type: COMPARATOR
Intervention: Viewing dentally neutral images (n=35)
Number of subjects: 70
Study 19500693 — intervention group
Group type: EXPERIMENTAL
Intervention: Biochemical response (normal ALT levels)
Number of subjects: 195
Study 19500693 — intervention group
Group type: EXPERIMENTAL
Intervention: Histologic response (reduction of necroinflammation grading by 2 points or more with no increase in fibrosis staging)
Number of subjects: 195
Study 19500693 — intervention group
Group type: EXPERIMENTAL
Intervention: Regression of cirrhosis
Number of subjects: 195
Study 19500693 — intervention group
Group type: EXPERIMENTAL
Intervention: Virologic response (levels of hepatitis B virus DNA below 10,000 copies/mL)
Number of subjects: 195
Study 16885758 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal administration of acetaminophen with codeine
Number of subjects: 75
Study 16885758 — intervention group
Group type: COMPARATOR
Intervention: Oral administration of acetaminophen with codeine
Number of subjects: 75
Study 15489842 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive therapy
Number of subjects: 0
Study 15489842 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of cerebral vessels, blood flow, circulatory and metabolic cerebral reserve
Number of subjects: 0
Study 11451173 — intervention group
Group type: EXPERIMENTAL
Intervention: lamivudine
Number of subjects: 24
Study 11451173 — intervention group
Group type: COMPARATOR
Intervention: HBIg
Number of subjects: 24
Study 9591892 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 147
Study 9591892 — intervention group
Group type: COMPARATOR
Intervention: Atenolol and/or placebo (control)
Number of subjects: 147
Study 8162673 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg ibuprofen
Number of subjects: 29
Study 8162673 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg ibuprofen
Number of subjects: 29
Study 8162673 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 3139138 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous salbutamol (12 micrograms/min continuous infusion for 4 hours)
Number of subjects: 76
Study 3139138 — intervention group
Group type: COMPARATOR
Intervention: Nebulised salbutamol (5 mg nebulised on admission, plus two more 5 mg doses at 30 minutes and 2 hours)
Number of subjects: 76
Study 31404750 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous flow (CF)
Number of subjects: 70
Study 31404750 — intervention group
Group type: EXPERIMENTAL
Intervention: Demand oxygen delivery system based on liquid oxygen (DODS-DL)
Number of subjects: 70
Study 31404750 — intervention group
Group type: EXPERIMENTAL
Intervention: Demand oxygen delivery system oxygen concentrator (DODS-DC)
Number of subjects: 70
Study 26302885 — intervention group
Group type: EXPERIMENTAL
Intervention: 8% CHO mouth rinse (MR)
Number of subjects: 6
Study 26302885 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% CHO ingestion (ING)
Number of subjects: 6
Study 26302885 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 6
Study 26480544 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm acupuncture combined with auricular acupuncture
Number of subjects: 130
Study 26480544 — intervention group
Group type: COMPARATOR
Intervention: Simple warm acupuncture
Number of subjects: 130
Study 22107250 — intervention group
Group type: EXPERIMENTAL
Intervention: High carbohydrate and whey protein diet (HCP)
Number of subjects: 16
Study 22107250 — intervention group
Group type: COMPARATOR
Intervention: Normal diet (CON)
Number of subjects: 16
Study 22107250 — intervention group
Group type: EXPERIMENTAL
Intervention: SIM60 (simulated match for 60 minutes)
Number of subjects: 16
Study 22107250 — intervention group
Group type: EXPERIMENTAL
Intervention: SIM90 (simulated match for 90 minutes)
Number of subjects: 16
Study 21745627 — intervention group
Group type: EXPERIMENTAL
Intervention: Small rice particles (500-1000 μm)
Number of subjects: 0
Study 21745627 — intervention group
Group type: COMPARATOR
Intervention: Large rice particles (>2000 μm)
Number of subjects: 0
Study 18823713 — intervention group
Group type: EXPERIMENTAL
Intervention: Stranded seeds (SS)
Number of subjects: 20
Study 18823713 — intervention group
Group type: COMPARATOR
Intervention: Loose seeds (LS)
Number of subjects: 20
Study 18823713 — intervention group
Group type: EXPERIMENTAL
Intervention: Stranded seeds (SS) and Loose seeds (LS)
Number of subjects: 20
Study 16959472 — intervention group
Group type: EXPERIMENTAL
Intervention: ondansetron (8 mg/day) combined with haloperidol (4-30 mg/day)
Number of subjects: 121
Study 16959472 — intervention group
Group type: COMPARATOR
Intervention: placebo combined with haloperidol (4-30 mg/day)
Number of subjects: 121
Study 14752676 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal saline with added potassium (NS)
Number of subjects: 54
Study 14752676 — intervention group
Group type: COMPARATOR
Intervention: Polyethylene glycol (PG)
Number of subjects: 54
Study 10786387 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine/pseudoephedrine sulfate
Number of subjects: 20
Study 9348566 — intervention group
Group type: EXPERIMENTAL
Intervention: MMC/UFT (20 mg of MMC sprinkled on the operating field, 6 mg/m2 of MMC intravenously on day 7 and monthly for 6 months, 400 mg/day of UFT orally for 1 year)
Number of subjects: 834
Study 9348566 — intervention group
Group type: COMPARATOR
Intervention: Surgery only (control group)
Number of subjects: 834
Study 9348566 — intervention group
Group type: EXPERIMENTAL
Intervention: MMC/UFT
Number of subjects: 834
Study 1316914 — intervention group
Group type: EXPERIMENTAL
Intervention: Percoll preparation
Number of subjects: 60
Study 1316914 — intervention group
Group type: COMPARATOR
Intervention: Swim-up preparation
Number of subjects: 60
Study 1316914 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 3916444 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural approach with extensive counselling by experienced dietitians (n = 99)
Number of subjects: 178
Study 3916444 — intervention group
Group type: COMPARATOR
Intervention: No continuous dietary advice (Control group, n = 79)
Number of subjects: 178
Study 3916444 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroups with and without sodium reduction
Number of subjects: 178
Study 29659016 — intervention group
Group type: EXPERIMENTAL
Intervention: Full attention condition (incidental encoding)
Number of subjects: 186
Study 29659016 — intervention group
Group type: EXPERIMENTAL
Intervention: Divided attention condition (incidental encoding)
Number of subjects: 186
Study 29659016 — intervention group
Group type: EXPERIMENTAL
Intervention: Full attention condition (intentional encoding)
Number of subjects: 186
Study 29659016 — intervention group
Group type: EXPERIMENTAL
Intervention: Divided attention condition (intentional encoding)
Number of subjects: 186